European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - duloxetine - diabetic neuropathies - psychoanaleptics, - treatment of diabetic peripheral neuropathic pain in adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - dipyridamole 150mg;   - modified release capsule - 150 mg - active: dipyridamole 150mg   excipient: acacia acetone dimeticone ethanol gelatin hypromellose hypromellose phthalate isopropyl alcohol methacrylic acid copolymer povidone purified talc purified water stearic acid tartaric acid triacetin

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - pramipexole dihydrochloride monohydrate - restless legs syndrome; parkinson disease - anti-parkinson drugs - mirapexin is indicated for treatment of the signs and symptoms of idiopathic parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).mirapexin is indicated for symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in dosages up to 0.54 mg of base (0.75 mg of salt).

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - pramipexole dihydrochloride monohydrate - restless legs syndrome; parkinson disease - anti-parkinson drugs - sifrol is indicated for treatment of the signs and symptoms of idiopathic parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, though to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).sifrol is indicated for symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in dosages up to 0.54 mg of base (0.75 mg of salt).

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - dipyridamole 25mg - tablet - 25 mg - active: dipyridamole 25mg excipient: magnesium stearate - indicated as an adjunct to oral anticoagulation for the prophylaxis of thromboembolism associated with mechanical prosthetic heart valves.

United Kingdom - English - myHealthbox

boehringer ingelheim international gmbh - tiotropium (as bromide monohydrate), olodaterol (as hydrochloride) - inhalation solution - 2.5 microgram/2.5 microgram per puff - drugs for obstructive airway diseases, adrenergics in combination with anticholinergics - it is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd)

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim international gmbh - tiotropium; olodaterol - inhalation solution - 2.5 µg/2.5 microgram(s) - anticholinergics; anticholinergics - drugs for obstructive airway diseases, adrenergics in combination with anticholinergics - it is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim international gmbh - tiotropium; olodaterol - inhalation solution - 2.5 µg/2.5 microgram(s) - anticholinergics; anticholinergics - drugs for obstructive airway diseases, adrenergics in combination with anticholinergics - it is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - dipyridamole 200mg;   - modified release capsule - 200 mg - active: dipyridamole 200mg   excipient: acacia acetone dimeticone ethanol gelatin   hypromellose hypromellose phthalate iron oxide red   iron oxide yellow isopropyl alcohol methacrylic acid copolymer povidone purified talc purified water     stearic acid tartaric acid titanium dioxide   triacetin

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - tasonermin - powder and solvent for solution for infusion - 1mg